Intended Use Study of the BD SurePath Plus™ Pap

Becton, Dickinson and Company (BD)

Status: Terminated

Conditions: Neoplasms by Histologic Type; Uterine Cervical Neoplasms; Uterine Cervical Cancer; Neoplasms, Squamous Cell; Neoplasms; Neoplasms, Glandular and Epithelial; Papilloma

Treatments: Device: BD SurePath Plus Pap test; Device: BD SurePath Pap test; Procedure: colposcopy with biopsy/ECC; Device: HPV DNA test

Study type: Interventional

Funder types: Industry

Identifiers

NCT01234480

TPO-10-06084

Details and patient eligibility

About

This study will provide data on the performance of the BD SurePath Plus™ Pap test for identifying high grade cervical disease. This study will be conducted with approximately 12,500 women undergoing routine cervical cancer screening, of whom women with abnormal cytology and/or positive HPV test will be selected to undergo colposcopy and biopsy/ECC. Subjects with abnormal cytology results with biopsy results of less than or equal to CIN1 or CIN2 untreated will be asked to return in 6-8 months for follow-up testing. Subjects may be asked to proceed to a longer-term follow-up study and undergo cytological evaluation annually for 3 years (separate study).

Full description

This is a pivotal, multi-center in vitro diagnostic study comparing the BD SurePath Plus Pap test to current practice (cytologic examination utilizing the BD SurePath liquid-based Pap test with conjunctive HPV testing) for the detection of cervical cancer and high-grade cervical disease (collectively referred to as CIN2+) in women.

The new BD SurePath Plus Pap Test combines a traditional Papanicolaou staining for cellular morphology, with brown nuclear immunostaining resulting from the over-expression of specific protein biomarkers, on one slide, to improve the detection of high-grade cervical disease and cervical cancer (collectively referred to as CIN2+).

Enrollment: 5,859 patients

Sex: Female

Ages: 18 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Study subjects must give voluntary written informed consent to participate in this study.

• Females ages 18 - 35 years, inclusive; or women at high- risk for cervical cancer or its precursor lesions.

High-risk is defined as:

• Have had a previous high-risk HPV positive test in the last 5 years; or
• Have had an abnormal Pap test (ASC-US or higher) in the last 5 years; or
• Have not been screened for cervical cancer by either a Pap test or HPV test in the last 5 years.

Exclusion criteria

• Subjects who are 36 years of age or greater who are not high risk, and/or:

  1. Have not had an abnormal Pap in the last 5 years; or
  2. Have not had a positive HPV test in the last 5 years; or
  3. Have been screened in the last 5 years without an abnormal Pap or HPV result

• Subjects known to be pregnant or planning to become pregnant prior to the potential six months follow-up visit (self-reported). Subjects who decide to become pregnant prior to the six-month follow up visit or found to be pregnant after the first visit, but prior to the six-month follow-up visit will be terminated from further study participation at that time

• Subjects who have had a prior complete or partial hysterectomy involving removal of the cervix.

• Subjects who have had an application of chemical compounds to the cervical area within the 24 hours prior to study entry, e.g., acetic acid, iodine, spermicide, douche, anti-fungal medications, etc.

• Subjects on whom conization, LEEP, laser surgery, or cryosurgery has been performed within the past five months.

• Subjects currently undergoing radiation and/or chemotherapy.

• Subjects under the age of 18.

• Subjects who have previously received a HPV vaccine with any number of doses.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5,859 participants in 2 patient groups

Participants with Cervical Disease

Experimental group

Description:

Participants positive for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.

Treatment:

Device: HPV DNA test

Device: BD SurePath Plus Pap test

Procedure: colposcopy with biopsy/ECC

Device: BD SurePath Pap test

Participants without Cervical Disease

Experimental group

Description:

Participants negative for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.

Treatment:

Device: HPV DNA test

Device: BD SurePath Plus Pap test

Device: BD SurePath Pap test